The market for psychedelic drugs to treat mental health conditions gets a big buy signal

• AtaiBeckley's lead drug BPL-003 (synthetic 5-MeO-DMT nasal spray) is in Phase 3 trials for treatment-resistant depression, which affects 4 million Americans, with potential $1-2 billion market opportunity if approved by early 2029
• Johnson & Johnson's Spravato (ketamine-derived nasal spray) demonstrates market viability with $2 billion in projected 2026 sales, up 40% year-over-year, serving as the commercial model for psychedelic treatments
• The psychedelic drugs market is estimated to grow from $4.63 billion in 2026 to $8.75 billion by 2031 (13.55% CAGR), with multiple companies like Compass and Definium expecting to launch products in 2027 following strong Phase 3 trial results

Market Summary: Psychedelic Drugs for Mental Health Treatment

Key Transaction

Eli Lilly announced acquisition of AtaiBeckley, a clinical-stage psychedelic drug developer, for up to $3.8 billion, signaling Big Pharma's growing acceptance of psychedelic-based mental health treatments.

Lead Asset and Market Opportunity

AtaiBeckley's BPL-003, a synthetic 5-MeO-DMT intranasal spray for treatment-resistant depression (TRD), has received FDA Breakthrough Therapy Designation and is in Phase 3 trials. Jefferies analysts project Phase 3 success by early 2029 could unlock a $1-2 billion TRD opportunity. The drug targets approximately 4 million Americans suffering from TRD.

Market Size and Growth

The psychedelic drugs market was valued at $4.08 billion in 2025, expected to reach $8.75 billion by 2031 (CAGR 13.55%). Mental illness affects 23.4% of U.S. adults—roughly 61.5 million people—creating substantial market opportunity.

Clinical Progress

• Definium Technologies: Phase 3 LSD-based drug DT120 showed significant efficacy in major depressive disorder, with additional anxiety disorder trials completing this month and September
• Compass Pathways: COMP360 (synthetic psilocybin) reported strong Phase 3 TRD results; commercial launch expected early 2027 with projected $50 million first-year sales
• Transcend Therapeutics: Acquired by Otsuka for $1.2 billion; TSND-201 (methylone) showing promising PTSD results

Benchmark Success

J&J's Spravato (ketamine-derived nasal spray) generated $584 million in Q1, up 40% year-over-year, on track for $2 billion annual sales, demonstrating commercial viability.

Regulatory Environment

President Trump's April executive order expedited FDA review processes for psychedelics. Multiple compounds have received fast-track vouchers and Breakthrough Therapy designations, though DEA reschedul